Cryo-Cell International, Inc. Short Interest Update

Cryo-Cell International, Inc. (NYSEAMERICAN:CCEL - Get Free Report) experienced a notable decline in short interest during December. As of December 15th, the total short interest was 19,000 shares, which marked a decrease of 5.9% from the 20,200 shares reported on November 30th. With an average trading volume of 19,600 shares, the days-to-cover ratio stands at 1.0 days. Approximately 0.6% of the company's shares are currently sold short.

Institutional Trading of Cryo-Cell International

In recent developments, an institutional investor has significantly increased its holdings in Cryo-Cell International. Geode Capital Management LLC raised its stake in the company by 68.5% in the third quarter, according to the latest reports filed with the Securities and Exchange Commission (SEC). After adding 16,203 shares, the fund now holds 39,860 shares of Cryo-Cell International, representing about 0.49% of its stock, valued at approximately $254,000. Institutional investors collectively own 10.44% of the company's shares.

Cryo-Cell International Trading Status

During midday trading on Wednesday, shares of NYSEAMERICAN:CCEL increased by 0.1%, reaching $7.41. A total of 9,303 shares were traded, which is below the average volume of 11,188. Cryo-Cell International has a market capitalization of $59.72 million, a price-to-earnings ratio of -6.99, and a beta of 0.49. Over the last 52 weeks, the stock has seen a low of $4.47 and a high of $9.50.

On October 15th, Cryo-Cell International reported its earnings. The company posted earnings of $0.13 per share for the quarter, surpassing the consensus estimate of $0.02 by $0.11. Revenue for the quarter reached $8.07 million. The company had a negative return on equity of 42.06% and a negative net margin of 28.03%.

Cryo-Cell International Dividend Announcement

Recently, Cryo-Cell International announced a dividend, which was paid on November 29th. The dividend of $0.25 per share was distributed to shareholders recorded on November 15th, and the ex-dividend date was the same day. The current payout ratio for the company stands at -94.34%.

About Cryo-Cell International

Cryo-Cell International, Inc. specializes in cellular processing and cryogenic storage, focusing on the collection and preservation of umbilical cord blood stem cells for family use. The company also offers cord tissue services that involve storing a section of the umbilical cord tissue, which is a source of mesenchymal stem cells used in regenerative medicine to treat various conditions, including heart disease, kidney disease, ALS, autoimmune diseases, and neurological disorders such as Alzheimer's and Parkinson's disease.

Further Reading

• Five stocks we like better than Cryo-Cell International
• What Is WallStreetBets and What Stocks Are They Targeting?
• Work and Play: Investing in the Rise of Bleisure Travel
• The 3 Best Retail Stocks to Shop for in August
• Top Dividend Stocks to Buy Now as Bond Yields Could Lower
• The Top 3 Healthcare Dividend Stocks to Buy and Hold
• SAP: AI Tailwinds Accelerating Enterprise Cloud Business

This report was generated using narrative science technology and financial data to provide accurate and timely information. All data have been reviewed for accuracy.

Should You Invest in Cryo-Cell International?

Before making any investment decision regarding Cryo-Cell International, it's essential to conduct thorough research.

Experts from major research firms continuously analyze stocks and may have alternative recommendations. Several analysts believe there are stocks currently available that show more potential than Cryo-Cell International.

If you're interested in learning more about which stocks are favored by institutional investors, resources are available to explore these trends.

Cryo-Cell, Investment, Stocks